by PEPID Newsroom | Feb 12, 2019 | Press & Media
PEPID, a leading global innovator in point-of-care technologies for the healthcare industry worldwide continued their success announcing the introduction of its cutting-edge Pharmacogenomics tool, named PEPID PGx. It is now showcasing at HIMSS 2019 this week. PEPID...
by PEPID Newsroom | Jan 28, 2019 | Alerts
Public Officials in Clark County, Washington are investigating a measles outbreak after reports of 34 confirmed cases and nine suspected cases since the first of January. Of the 34 cases, thirty-two have been confirmed to be unimmunized, while four remain unverified....
by PEPID Newsroom | Jan 7, 2019 | Press & Media
January 7, 2019 — Phoenix, AZ — Trusted medical information and point-of-care solutions provider, PEPID, LLC is pleased to announce another partnered advance towards patient-centered care. Moving forward with PEPID’s Bedside Education in Florida State University’s...
by PEPID Newsroom | Jan 2, 2019 | Alerts
The FDA has approved Elxonris (tagraxofusperzs) infusion to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients two years and older. This is the first FDA approved therapy specifically for BPDCN. Elzonris is a targeted investigational therapy...
by PEPID Newsroom | Jan 2, 2019 | Alerts
The injection Ultomirus (ravulizumab) has been approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is a long-acting complement inhibitor that prevents hemolysis. Richard Pazdur, M.D., director of the FDA’s Oncology...
